Last reviewed · How we verify
Suzetrigine (SUZ)
Suzetrigine is a selective sodium channel inhibitor that reduces neuronal excitability by blocking voltage-gated sodium channels.
Suzetrigine is a selective sodium channel inhibitor that reduces neuronal excitability by blocking voltage-gated sodium channels. Used for Acute pain (post-operative pain).
At a glance
| Generic name | Suzetrigine (SUZ) |
|---|---|
| Also known as | VX-548 |
| Sponsor | Vertex Pharmaceuticals Incorporated |
| Drug class | Selective sodium channel inhibitor |
| Target | Voltage-gated sodium channels (Nav) |
| Modality | Small molecule |
| Therapeutic area | Pain management / Neurology |
| Phase | FDA-approved |
Mechanism of action
Suzetrigine selectively inhibits sodium channels on sensory neurons, reducing the propagation of pain signals to the central nervous system. By decreasing neuronal firing in pain pathways, it provides analgesia without the systemic effects associated with non-selective sodium channel blockers. This mechanism makes it particularly suited for localized or systemic pain management.
Approved indications
- Acute pain (post-operative pain)
Common side effects
- Dizziness
- Headache
- Nausea
- Paresthesia
Key clinical trials
- Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy (PHASE3)
- Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants (PHASE1)
- Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy (PHASE3)
- Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN) (PHASE3)
- A Single-Arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Aesthetic or Reconstructive Surgeries (PHASE4)
- A Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Selected Surgeries (PHASE4)
- Suzetrigine for Acute Pain Control in Patients With Multiple Rib Fractures (PHASE4)
- RCT: Suzetrigine vs Norco for Post-op Pain (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Suzetrigine (SUZ) CI brief — competitive landscape report
- Suzetrigine (SUZ) updates RSS · CI watch RSS
- Vertex Pharmaceuticals Incorporated portfolio CI